On May 26, Abivax S.A. rose 5.8% overnight, trading at $129.06/share. The move was driven by the company's financial disclosure showing robust liquidity that eased concerns over its R&D sustainability.

According to the earnings report, Abivax held cash, cash equivalents, and short-term investments totaling €491.6 million as of March 31, with a projected cash runway extending into Q4 of the following year based on current operating assumptions. This strong balance sheet directly addressed market concerns about the company's ability to fund ongoing clinical programs. Prior to the report, institutional sentiment had already turned bullish, with the majority of sell-side analysts maintaining buy ratings and target prices above the prevailing stock price, focusing on the impact of financing and royalty arrangements on the company's expense and cash flow trajectory.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate immune responses in chronic inflammatory diseases. Its lead candidate, obefazimod, is currently in Phase 3 development for the treatment of moderately to severely active ulcerative colitis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)